Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 11:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 913–936 of 2,208 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Blinded (placebo) Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Intranasal Capsaicin Treatment for Non-Allergic Irritant Rhinitis

NCT02493257
View directory record Official record
Conditions
Nonallergic Irritant Rhinitis
Interventions
Capsaicin, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 70 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 17, 2020 · Synced Oct 16, 2026, 11:17 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

RSV-F Vaccine Dose Ranging Study in Young Women

NCT01704365
View directory record Official record
Conditions
Respiratory Syncytial Virus (RSV)
Interventions
Low dose RSV-F Vaccine with Adjuvant, Low dose RSV-F Vaccine without Adjuvant, High dose RSV-F Vaccine with Adjuvant, High dose RSV-F Vaccine without Adjuvant, Low dose RSV-F Vaccine with Adjuvant [Bedside Mixing], Placebo
Biological
Lead sponsor
Novavax
Industry
Eligibility
18 Years to 35 Years · Female only
Enrollment
330 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
4
States / cities
Anaheim, California • Rockville, Maryland • Mt. Pleasant, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2014 · Synced Oct 16, 2026, 11:17 AM EDT
Completed Not applicable Interventional Results available

Methylphenidate for Depressed Cancer Patients Receiving Palliative Care

NCT00129467
View directory record Official record
Conditions
Depression, Palliative Care, Cancer, Mental Disorder
Interventions
Methylphenidate, Placebo, Selective Serotonin Uptake Inhibitor (SSRI)
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 24, 2015 · Synced Oct 16, 2026, 11:17 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Neuroimmune Dysfunction in Alcohol Use Disorder

NCT04210713
View directory record Official record
Conditions
Alcohol Drinking, Alcohol-Related Disorders, Disease, Inflammation, Alcoholism, Cognitive Dysfunction, Pathologic Processes, Drinking Behavior, Substance-Related Disorders, Chemically-Induced Disorders, Mental Disorder, Cognition Disorder, Neurocognitive Disorders, Minocycline, Anti-Bacterial Agents, Anti-Infective Agents
Interventions
Minocycline, Sugar pill
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
25 Years to 65 Years
Enrollment
142 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 1, 2023 · Synced Oct 16, 2026, 11:17 AM EDT
Completed No phase listed Observational

A Follow-up Study to Assess Long-term Immunogenicity and Safety of NicVAX/Placebo as an Aid to Smoking Cessation

NCT01304810
View directory record Official record
Conditions
Smoking Cessation, Nicotine Dependence
Interventions
NicVAX vaccine, Placebo
Biological
Lead sponsor
Nabi Biopharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
12
States / cities
Newport Beach, California • San Diego, California • Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated May 14, 2012 · Synced Oct 16, 2026, 11:17 AM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Electronic Cigarette Withdrawal Syndrome

NCT06066996
View directory record Official record
Conditions
E-cigarette Use, Withdrawal
Interventions
Transdermal Nicotine Patch, Placebo Nicotine Patch
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 55 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 16, 2026, 11:17 AM EDT
Completed Phase 1 Interventional

Defined Green Tea Catechin Extract in Preventing Esophageal Cancer in Patients With Barrett's Esophagus

NCT00233935
View directory record Official record
Conditions
Barrett Esophagus
Interventions
placebo, defined green tea catechin extract
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
3
States / cities
New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 11, 2014 · Synced Oct 16, 2026, 11:17 AM EDT
Terminated Phase 3 Interventional Results available

To Evaluate the Effect of Liraglutide Versus Glimepiride (Amaryl®) on Haemoglobin A1c

NCT00294723
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
liraglutide, glimepiride, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 80 Years
Enrollment
746 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
102
States / cities
Concord, California • Escondido, California • Fullerton, California + 83 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2017 · Synced Oct 16, 2026, 11:17 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP).

NCT04188379
View directory record Official record
Conditions
Primary Immune Thrombocytopenia
Interventions
efgartigimod, Placebo
Biological · Other
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
9
States / cities
Tucson, Arizona • Washington D.C., District of Columbia • Jacksonville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2025 · Synced Oct 16, 2026, 11:17 AM EDT
Not listed Phase 2 Interventional

Trial of Steroids in Pediatric Acute Lung Injury/ARDS

NCT01274260
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome (ARDS), Acute Lung Injury (ALI)
Interventions
methylprednisolone, Normal Saline (0.9%)
Drug
Lead sponsor
University of Tennessee
Other
Eligibility
1 Month to 18 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated May 28, 2014 · Synced Oct 16, 2026, 11:17 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Lipidomics Screening of Celecoxib in ex Vivo Human Whole Blood Assay - Part B

NCT02413203
View directory record Official record
Conditions
Healthy
Interventions
Celecoxib, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 16, 2026, 11:17 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis

NCT06558279
View directory record Official record
Conditions
Myasthenia Gravis, Ocular
Interventions
Efgartigimod PH20 SC, Placebo PH20 SC
Combination Product · Other
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
20
States / cities
Scottsdale, Arizona • Loma Linda, California • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 16, 2026, 11:17 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Clinical Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LEZ763

NCT01619332
View directory record Official record
Conditions
Type II Diabetes
Interventions
Placebo, Sitagliptin, LEZ763
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
6
States / cities
Chula Vista, California • Miami, Florida • Orlando, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Oct 16, 2026, 11:17 AM EDT
Completed Not applicable Interventional

Placebo Controlled Study of Antibiotic Treatment of Soft Tissue Infection

NCT00187759
View directory record Official record
Conditions
Soft Tissue Infections
Interventions
cephalexin
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 7, 2015 · Synced Oct 16, 2026, 11:17 AM EDT
Completed Phase 3 Interventional Results available

A Study of the Efficacy and Safety of Etrolizumab in Participants With Ulcerative Colitis Who Have Been Previously Exposed to Tumor Necrosis Factor (TNF) Inhibitors

NCT02100696
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Etrozulimab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 80 Years
Enrollment
609 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
38
States / cities
Birmingham, Alabama • La Jolla, California • San Diego, California + 32 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2021 · Synced Oct 16, 2026, 11:17 AM EDT
Terminated Early Phase 1 Interventional Results available

Topical Timolol 0.5% Solution for Proliferating Infantile Hemangiomas

NCT01147601
View directory record Official record
Conditions
Hemangioma, Infant
Interventions
topical 0.5% Timolol, Control (placebo) group
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
1 Month to 8 Months
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 5, 2017 · Synced Oct 16, 2026, 11:17 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity Study of the Hepatitis B Vaccine, HEPLISAV™, Compared to Engerix-B® Vaccine

NCT02117934
View directory record Official record
Conditions
Healthy
Interventions
HEPLISAV, Engerix-B
Biological
Lead sponsor
Dynavax Technologies Corporation
Industry
Eligibility
18 Years to 70 Years
Enrollment
8,374 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
40
States / cities
Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2019 · Synced Oct 16, 2026, 11:17 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Effects of Hip Bump Manipulation Versus Sham Treatment in Healthy Adults

NCT07025434
View directory record Official record
Conditions
Assessment of Hip Strength, Range of Motion, EMG Activation, and Landing Mechanics in Healthy Subjects, Healthy Adult Subjects
Interventions
Hip Bump Manipulation, Sham (No Treatment)
Procedure
Lead sponsor
Dominican University New York
Other
Eligibility
18 Years to 45 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Orangeburg, New York
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 16, 2026, 11:17 AM EDT
Completed Phase 2 Interventional Results available

Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis Patients

NCT01286012
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Soluble Ferric Pyrophosphate in liquid bicarbonate, Placebo: Conventional liquid bicarbonate, Erythrocyte Stimulating Agent (ESA), Intravenous (IV) Iron
Drug
Lead sponsor
Rockwell Medical Technologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
22
States / cities
Birmingham, Alabama • Tempe, Arizona • Granada Hills, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2018 · Synced Oct 16, 2026, 11:17 AM EDT
Completed Phase 3 Interventional Results available

Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer

NCT00704730
View directory record Official record
Conditions
Thyroid Cancer
Interventions
XL184, Placebo
Drug
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2020
U.S. locations
29
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 26 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2021 · Synced Oct 16, 2026, 11:17 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Methylphenidate Treatment of Attention Deficits in Epilepsy

NCT02178995
View directory record Official record
Conditions
Epilepsy, Cognitive Deficits, Attention Deficits
Interventions
Methylphenidate
Drug
Lead sponsor
Kimford Jay Meador
Other
Eligibility
18 Years to 65 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 16, 2026, 11:17 AM EDT
Completed Phase 3 Interventional Results available

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

NCT00783692
View directory record Official record
Conditions
Crohn's Disease
Interventions
vedolizumab, Placebo
Drug · Other
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
110
States / cities
Birmingham, Alabama • Los Angeles, California • Montebello, California + 91 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2014 · Synced Oct 16, 2026, 11:17 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study To Investigate A Clostridium Difficile Vaccine In Healthy Adults Aged 50 to 85 Years, Who Will Each Receive 3 Doses Of Vaccine.

NCT02117570
View directory record Official record
Conditions
Clostridium Difficile Associated Disease
Interventions
Clostridium difficile vaccine, Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
50 Years to 85 Years
Enrollment
185 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
12
States / cities
DeLand, Florida • Savannah, Georgia • Stockbridge, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2017 · Synced Oct 16, 2026, 11:17 AM EDT
Completed Phase 3 Interventional Results available

Evaluating Outcomes in Cardiac Surgery Patients Who Receive Sugammadex vs. Placebo

NCT05801679
View directory record Official record
Conditions
Surgery
Interventions
Sugammadex, Placebo
Drug · Other
Lead sponsor
Endeavor Health
Other
Eligibility
21 Years to 90 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 16, 2026, 11:17 AM EDT